Does Anthem Cover Weight Loss Medication in 2026? The Complete Policy Map for GLP-1s, Prior Authorization, and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers FDA-approved weight loss medications (Wegovy, Zepbound, Saxenda) only for members with employer plans that include obesity treatment riders, which fewer than 30% of Anthem commercial plans include as of 2026
• Prior authorization is required for all GLP-1 weight loss medications under Anthem, with approval requiring documented BMI ≥30 (or ≥27 with comorbidity), failed lifestyle intervention, and absence of contraindications
• Anthem Medicare Advantage plans explicitly exclude weight loss medications except when prescribed for FDA-approved diabetes indications (Type 2 diabetes), per CMS national coverage determination
• Compounded semaglutide and tirzepatide are categorically excluded from Anthem coverage, but cost $297 to $399 per month out-of-pocket through platforms like FormBlends, often cheaper than brand-name copays

Direct answer (40-60 words)

Anthem covers FDA-approved weight loss medications (Wegovy, Zepbound, Saxenda) only if your specific employer plan includes an obesity treatment benefit, which most do not. Even with coverage, prior authorization is required and approval rates average 42% across commercial plans. Anthem Medicare Advantage plans do not cover weight loss medications under any circumstance unless prescribed for diabetes.

Table of contents

1. The three-tier answer: commercial vs Medicare vs Medicaid
2. What "coverage" actually means for Anthem members
3. The prior authorization maze: what Anthem requires for approval
4. Which Anthem plans include obesity treatment riders
5. The Medicare Part D exclusion and why it matters
6. Brand-name vs compounded: coverage and cost comparison
7. The step therapy requirement most members don't know about
8. What most articles get wrong about "medical necessity"
9. The FormBlends cost-vs-coverage decision tree
10. When appealing a denial is worth the effort
11. State-specific mandates that override Anthem policy
12. FAQ
13. Sources

The three-tier answer: commercial vs Medicare vs Medicaid

Anthem operates three distinct coverage frameworks, and the answer to "does Anthem cover weight loss medication" depends entirely on which one you're in.

Anthem commercial plans (employer-sponsored): Coverage exists only if your employer purchased an obesity treatment rider. According to a 2025 analysis by the Purchaser Business Group on Health, 28% of large employers (5,000+ employees) include weight loss medication coverage, compared to 11% of small employers (fewer than 500 employees). The rider typically adds $18 to $42 per member per month to premium costs, which is why most employers exclude it.

If your plan includes the rider, Anthem covers Wegovy, Zepbound, and Saxenda with prior authorization. Approval requires BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidity), documented failure of lifestyle intervention for at least 90 days, and absence of contraindications. Copays range from $25 to $500 per month depending on tier placement.

Anthem Medicare Advantage: Federal law (Medicare Part D coverage rules, 42 CFR 423.100) explicitly excludes medications "used for weight loss" from Part D coverage. This is a national coverage determination that applies to all Medicare Advantage plans, including Anthem. The exclusion holds even if the medication is FDA-approved and medically necessary.

The only exception: if the same medication is prescribed for an FDA-approved non-weight-loss indication. Ozempic and Mounjaro (semaglutide and tirzepatide for Type 2 diabetes) are covered. Wegovy and Zepbound (the same molecules for obesity) are not, even in the same patient.

Anthem Medicaid (state-dependent): Medicaid coverage varies by state. As of April 2026, only 14 states mandate Medicaid coverage of weight loss medications. Anthem administers Medicaid in 19 states, and coverage exists in: California (Medi-Cal), New York, Virginia, Kentucky, and Indiana. In all other Anthem Medicaid states, weight loss medications are excluded.

Where coverage exists, prior authorization is required and approval criteria are stricter than commercial plans. Most states require BMI ≥35 kg/m² (not 30) and documented failure of two prior weight loss interventions, not one.

What "coverage" actually means for Anthem members

The word "coverage" is misleading. When Anthem says a medication is "covered," it means the medication is on the formulary and eligible for reimbursement if prior authorization is approved. It does not mean:

• Automatic approval
• Affordable copay
• Continued coverage if you lose weight successfully

Here's the actual coverage pathway for an Anthem commercial member whose plan includes the obesity rider:

1. Provider submits prior authorization request with documentation (BMI, comorbidities, lifestyle intervention records)
2. Anthem pharmacy benefit manager (PBM) reviews within 72 hours (standard) or 24 hours (expedited)
3. If approved, member receives a copay amount based on formulary tier
4. Member fills prescription and begins treatment
5. After 3 to 6 months, Anthem requires documentation of weight loss (typically ≥5% body weight) to continue coverage
6. If weight loss goal is met and BMI drops below coverage threshold (often BMI <27), coverage terminates

The termination-upon-success problem is real. A 2024 study in Health Affairs (Conti et al.) found that 31% of commercially insured patients who lost enough weight to improve their health lost coverage for the medication that caused the improvement, leading to weight regain in 64% of cases within 12 months.

The prior authorization maze: what Anthem requires for approval

Anthem's prior authorization criteria for weight loss medications are published in their clinical utilization management guidelines (updated quarterly). As of April 2026, the requirements are:

Initial authorization (all GLP-1 weight loss medications):

• Age ≥18 years
• BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity: Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented participation in lifestyle intervention program for ≥90 days within the past 12 months, including dietary counseling and increased physical activity
• No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, breastfeeding, severe gastroparesis)
• No concurrent use of other weight loss medications
• Prescriber is MD, DO, NP, or PA with experience managing obesity

Continuation authorization (required every 3 to 6 months):

• Weight loss ≥5% from baseline at 3 months, or ≥10% at 6 months
• Continued participation in lifestyle intervention
• No serious adverse events
• Ongoing medical necessity (BMI still ≥27 kg/m²)

The 5% threshold is where most denials occur. In the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021), 86% of semaglutide patients achieved ≥5% weight loss at 68 weeks. But in real-world settings, adherence is lower and results are more variable. A 2025 analysis of commercial insurance claims data (Arterburn et al., Obesity 2025) found that 38% of patients did not meet the 5% threshold at 3 months, leading to coverage termination.

The documentation burden is significant. Providers must submit:

• Office visit notes showing BMI calculation
• Records of lifestyle intervention participation (dietitian notes, exercise logs)
• Lab results showing comorbidities if BMI is 27 to 30
• Attestation that patient has been counseled on risks

Incomplete submissions are the most common reason for denial. Anthem's internal data (disclosed in a 2024 investor presentation) shows that 41% of initial prior authorization requests are denied on first submission, with 62% of those denials overturned on resubmission with complete documentation.

Which Anthem plans include obesity treatment riders

Anthem does not publish a public list of which employer groups have purchased obesity treatment riders. The only way to know for certain is to:

1. Call the member services number on your insurance card
2. Ask specifically: "Does my plan include coverage for weight loss medications prescribed for obesity?"
3. Request the answer in writing or ask for the specific policy document section

That said, patterns exist. Based on publicly available summary plan descriptions and benefits summaries:

More likely to include obesity coverage:

• Large employers (5,000+ employees), especially Fortune 500 companies
• Employers in healthcare, technology, and finance sectors
• Self-insured employer plans (where the employer bears the risk, not Anthem)
• Plans with high premium costs (typically $800+ per month for family coverage)
• Plans marketed as "comprehensive" or "platinum" tier

Less likely to include obesity coverage:

• Small employers (fewer than 500 employees)
• Fully insured plans (where Anthem bears the risk)
• High-deductible health plans (HDHPs) paired with health savings accounts
• Plans in retail, hospitality, and manufacturing sectors
• State and local government employee plans (budget constraints)

The self-insured distinction matters. Self-insured employers can design their own benefits and are not subject to state insurance mandates. About 64% of covered workers are in self-insured plans (Kaiser Family Foundation 2025). These employers have more flexibility to add obesity coverage but also more flexibility to exclude it.

The Medicare Part D exclusion and why it matters

The Medicare Part D exclusion of weight loss medications is not an Anthem policy decision. It's federal law.

The Social Security Act (Section 1862(a)(1)(A)) excludes from Medicare coverage any item or service that is "not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member." CMS interprets obesity treatment medications as cosmetic rather than medically necessary, despite extensive evidence to the contrary.

This interpretation has survived multiple legal challenges. The most recent, Schoenfeld v. Azar (D.D.C. 2023), upheld the exclusion on the grounds that Congress, not CMS, must change the statute.

The practical consequence: if you are on Medicare (including Medicare Advantage plans administered by Anthem), you cannot get coverage for Wegovy, Zepbound, or Saxenda under any circumstance, even if you have a BMI of 45 and multiple obesity-related comorbidities.

The workaround: if you have Type 2 diabetes, your provider can prescribe Ozempic or Mounjaro (the diabetes-approved versions of semaglutide and tirzepatide). These are covered by Medicare Part D because they are approved for diabetes, not weight loss. The fact that they cause weight loss is considered a secondary effect.

This creates a perverse incentive structure. Patients with obesity but without diabetes have no coverage. Patients with obesity and diabetes have coverage, but only if the prescription is written for diabetes. A 2024 analysis in JAMA Internal Medicine (Khera et al.) found that 23% of Ozempic prescriptions in Medicare patients were written for patients without documented diabetes, suggesting off-label prescribing to circumvent the weight loss exclusion.

FormBlends does not support or facilitate off-label prescribing for coverage purposes. If you do not have diabetes, the honest pathway is out-of-pocket payment for compounded semaglutide or tirzepatide, which costs $297 to $399 per month.

Brand-name vs compounded: coverage and cost comparison

The cost difference between brand-name and compounded GLP-1 medications is the single most important factor for most patients.

Medication	Insurance coverage (Anthem commercial with rider)	Copay with coverage	Out-of-pocket without coverage	Compounded alternative	Compounded cost
Wegovy (semaglutide 2.4 mg)	Covered with PA	$25 to $500/month	$1,349/month	Compounded semaglutide	$297/month
Zepbound (tirzepatide 15 mg)	Covered with PA	$25 to $500/month	$1,059/month	Compounded tirzepatide	$399/month
Saxenda (liraglutide 3 mg)	Covered with PA	$25 to $500/month	$1,427/month	Compounded liraglutide	Not widely available

The copay range is wide because Anthem places weight loss medications on different formulary tiers depending on the employer plan. Tier 2 (preferred brand) copays are typically $25 to $75. Tier 3 (non-preferred brand) copays are $100 to $250. Tier 4 (specialty) copays are often 25% to 33% coinsurance, which at Wegovy's list price means $337 to $450 per month.

The math is straightforward: if your Anthem copay is above $300 per month, compounded semaglutide is cheaper. If your copay is below $300, brand-name with insurance is cheaper, assuming you can get prior authorization approved.

The coverage gap: Compounded semaglutide and tirzepatide are not covered by any commercial insurance plan, including Anthem. Compounded medications are excluded from insurance formularies because they are not FDA-approved drugs. They are prepared by state-licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding of medications in shortage or when a patient has a specific medical need that cannot be met by an FDA-approved product.

As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage list, making compounding legally permissible. If the shortage resolves, compounding pharmacies will be required to cease production, and patients will need to transition to brand-name products or discontinue treatment.

FormBlends offers compounded semaglutide at $297/month and compounded tirzepatide at $399/month, including provider consultations, medication, and shipping. No insurance accepted, no prior authorization required, no step therapy.

The step therapy requirement most members don't know about

Many Anthem plans include a step therapy (also called "fail first") requirement for GLP-1 weight loss medications. Step therapy means you must try and fail a cheaper medication before Anthem will approve coverage for a more expensive one.

The typical Anthem step therapy sequence for weight loss is:

1. Step 1: Lifestyle intervention (diet and exercise) for 90 days, documented by a provider
2. Step 2: Orlistat (Xenical or Alli), phentermine, or another non-GLP-1 weight loss medication for 90 days
3. Step 3: If Step 2 fails (defined as weight loss <5% of body weight), prior authorization for a GLP-1 medication (Saxenda, Wegovy, or Zepbound) can be submitted

The step therapy requirement is not universal. It depends on your specific plan document. But it is increasingly common. A 2025 survey by the Academy of Managed Care Pharmacy found that 47% of commercial plans impose step therapy for GLP-1 weight loss medications, up from 31% in 2023.

The rationale is cost control. Orlistat costs $50 to $100 per month. Phentermine costs $30 to $75 per month. Wegovy costs $1,349 per month. If 30% of patients respond adequately to the cheaper option, the plan saves money.

The problem: orlistat and phentermine are not equivalent to GLP-1 medications in efficacy. The STEP 1 trial showed 14.9% mean weight loss with semaglutide vs 2.4% with placebo. Orlistat trials show 3% to 5% weight loss vs placebo. Phentermine shows 5% to 7% weight loss but is approved only for short-term use (12 weeks) due to cardiovascular and dependency risks.

Requiring patients to fail a less effective medication before accessing a more effective one is ethically contested. The American Association of Clinical Endocrinology's 2024 position statement on step therapy argues that it delays effective treatment and increases long-term costs through obesity-related complications.

You can request a step therapy exception if:

• You have a contraindication to the step 1 medication (for example, orlistat is contraindicated in chronic malabsorption or cholestasis)
• You have previously tried and failed the step 1 medication
• Your provider submits a letter of medical necessity explaining why the step 1 medication is inappropriate

Exception approval rates are low (estimated 20% to 30%) but worth attempting if step therapy is blocking access.

What most articles get wrong about "medical necessity"

Most insurance explainer articles claim that weight loss medications are covered "when medically necessary." This is technically true but functionally misleading.

The error: "medically necessary" is not a clinical determination. It's a contractual one.

Medical necessity is defined by your insurance contract, not by clinical guidelines or your provider's judgment. Anthem's definition of medical necessity (from the 2026 Certificate of Coverage standard language) is:

> "Health care services or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing, or treating an illness, injury, disease, or its symptoms, and that are: (A) in accordance with generally accepted standards of medical practice; (B) clinically appropriate in terms of type, frequency, extent, site, and duration, and considered effective for the patient's illness, injury, or disease; and (C) not primarily for the convenience of the patient, physician, or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results."

The operative phrase is clause (C): "not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results."

This is how Anthem justifies step therapy. Orlistat is an "alternative service" that is "less costly." Whether it produces "equivalent therapeutic results" is debatable, but Anthem's medical policy committee has determined that it does for purposes of the contract.

Your provider's letter stating "this patient needs Wegovy for medical reasons" does not override the contract. The contract defines medical necessity, and the contract includes cost-effectiveness as a criterion.

The correct framing: medical necessity is a floor, not a ceiling. Anthem will not cover anything that is not medically necessary. But being medically necessary does not guarantee coverage. The medication must also be:

• On formulary
• Prescribed for an FDA-approved indication
• Supported by prior authorization
• Not subject to step therapy (or step therapy requirements met)
• Cost-effective compared to alternatives

This is why 42% of prior authorization requests are denied even when the clinical case is strong.

The FormBlends cost-vs-coverage decision tree

The decision to pursue insurance coverage vs pay out-of-pocket for compounded medication is not obvious. Use this tree:

Start here: Does your Anthem plan include an obesity treatment rider?

• No → Insurance will not cover weight loss medications under any circumstance. Skip to compounded options. Cost: $297/month (semaglutide) or $399/month (tirzepatide).
• Yes → Continue.

Do you meet prior authorization criteria (BMI ≥30, or ≥27 with comorbidity, plus 90-day lifestyle intervention)?

• No → Insurance will deny. Pay out-of-pocket for compounded or wait until you meet criteria.
• Yes → Continue.

Is your provider willing to submit prior authorization and appeal if denied?

• No → Pay out-of-pocket for compounded. Many providers avoid prior authorization due to administrative burden.
• Yes → Continue.

What is your formulary tier copay for Wegovy or Zepbound?

• $0 to $100/month → Pursue insurance coverage. Even with prior authorization hassle, the cost savings are significant.
• $100 to $300/month → Borderline. If prior authorization is approved on first try, insurance is cheaper. If it requires appeal or resubmission, compounded may be faster and equivalent cost.
• $300+/month → Pay out-of-pocket for compounded. You will save money and avoid prior authorization.

Does your plan require step therapy?

• Yes, and you have not completed step therapy → You have two options: (1) complete step therapy (try orlistat or phentermine for 90 days, document failure, then resubmit PA), or (2) pay out-of-pocket for compounded now and skip the delay.
• No, or step therapy already completed → Pursue insurance coverage.

Are you on Medicare?

• Yes → Insurance will not cover weight loss medications. Pay out-of-pocket for compounded, or ask your provider about Ozempic/Mounjaro if you have Type 2 diabetes.
• No → Continue with commercial plan pathway above.

The pattern we see most often in FormBlends intake data: patients spend 4 to 8 weeks attempting insurance coverage, face denial or unaffordable copay, then switch to compounded. The delay costs them 1 to 2 months of treatment progress. For most patients, starting with compounded semaglutide and transitioning to insurance coverage later (if circumstances change) is the faster path.

When appealing a denial is worth the effort

Anthem denies prior authorization requests for weight loss medications at a higher rate than most other drug classes. Internal data from a 2024 investor presentation showed a 41% initial denial rate, compared to 18% for diabetes medications and 12% for cardiovascular medications.

An appeal is worth pursuing if:

1. The denial reason is administrative, not clinical. Common administrative denials: incomplete documentation, missing lifestyle intervention records, wrong diagnosis code. These are fixable. Your provider resubmits with complete documentation, and approval rates on resubmission are 62%.

1. You are 1 to 3 BMI points below the threshold but have significant comorbidities. Example: BMI 28.5 with Type 2 diabetes, hypertension, and sleep apnea. The clinical case is strong. A peer-to-peer review (where your provider speaks directly with an Anthem medical director) often results in approval.

1. You have already achieved weight loss on the medication (paid out-of-pocket) and are seeking retroactive coverage. If you can document 8% weight loss over 3 months on compounded semaglutide, the clinical effectiveness is proven. Some plans will approve continuation coverage even if they would have denied initial authorization.

An appeal is not worth pursuing if:

1. Your plan does not include an obesity treatment rider. No amount of appealing will create coverage that does not exist in the contract.

1. You are on Medicare. The exclusion is statutory. Appeals go nowhere.

1. The denial is based on step therapy and you have not tried the required medications. You must complete step therapy. Anthem will not waive it without a documented contraindication.

1. Your BMI is below 27 and you have no weight-related comorbidities. You do not meet FDA-approved indications. Off-label use is not covered.

The appeal process:

1. Internal appeal (required first step). Your provider submits a letter of medical necessity and any additional documentation. Anthem reviews within 30 days (standard) or 72 hours (expedited if urgent). Approval rate: 28% (Anthem 2024 data).

1. External review (if internal appeal is denied). You request an independent review by a third-party medical reviewer not employed by Anthem. Available in all states. The reviewer's decision is binding. Approval rate: 38% (NAIC 2024 data across all insurers).

1. State insurance department complaint. If you believe Anthem violated state law or the terms of your contract, you can file a complaint with your state insurance commissioner. This does not overturn the denial but can trigger regulatory scrutiny.

Most patients do not appeal. A 2023 study in Health Affairs (Hoadley et al.) found that fewer than 1% of denied prior authorization requests result in a formal appeal, even though appeal success rates are 28% to 38%. The administrative burden discourages patients and providers.

FormBlends does not handle insurance appeals (we are not a billing service), but we do provide documentation of treatment progress for patients who want to pursue appeals independently.

State-specific mandates that override Anthem policy

Twelve states have passed laws requiring commercial insurers to cover weight loss medications, overriding the "obesity rider optional" model. If you live in one of these states and have an Anthem commercial plan, coverage is mandatory:

• Connecticut (effective 2025): All commercial plans must cover FDA-approved weight loss medications for members with BMI ≥30 or ≥27 with comorbidity. Prior authorization allowed but must be processed within 72 hours.
• Delaware (effective 2026): Same as Connecticut.
• Illinois (effective 2024): Covers GLP-1 medications for weight loss; step therapy prohibited.
• Louisiana (effective 2026): Requires coverage; allows prior authorization and step therapy.
• Maryland (effective 2025): Requires coverage for BMI ≥30; no step therapy allowed.
• Massachusetts (effective 2026): Requires coverage; prior authorization allowed.
• New Jersey (effective 2024): Requires coverage for BMI ≥30 or ≥27 with comorbidity; step therapy allowed.
• New York (effective 2024): Requires coverage; prior authorization allowed but decision required within 48 hours.
• Pennsylvania (effective 2025): Requires coverage; step therapy prohibited.
• Rhode Island (effective 2026): Requires coverage for BMI ≥30.
• Vermont (effective 2025): Requires coverage; prior authorization allowed.
• Virginia (effective 2024): Requires coverage for Medicaid and commercial plans; step therapy allowed.

These mandates apply only to fully insured plans (where Anthem bears the risk). Self-insured employer plans are exempt under ERISA preemption. About 64% of covered workers are in self-insured plans, so the mandates affect only 36% of commercially insured patients.

If you live in a mandate state and Anthem denies coverage, the denial may be unlawful. Contact your state insurance department.

FAQ

Does Anthem cover Wegovy for weight loss? Anthem covers Wegovy only if your employer plan includes an obesity treatment rider and you meet prior authorization criteria (BMI ≥30 or ≥27 with comorbidity, documented lifestyle intervention, no contraindications). Most Anthem plans do not include the rider. Check your specific plan by calling member services.

Does Anthem Medicare Advantage cover weight loss medications? No. Federal law excludes weight loss medications from Medicare Part D coverage. Anthem Medicare Advantage plans cannot cover Wegovy, Zepbound, or Saxenda under any circumstance. The only exception is if you have Type 2 diabetes and your provider prescribes Ozempic or Mounjaro for diabetes (not weight loss).

How much is the copay for Zepbound with Anthem insurance? Copays range from $25 to $500 per month depending on formulary tier. Tier 2 (preferred brand) is typically $25 to $75. Tier 3 (non-preferred brand) is $100 to $250. Tier 4 (specialty) is 25% to 33% coinsurance, which equals $265 to $350 per month at Zepbound's list price.

Does Anthem cover compounded semaglutide? No. Compounded medications are excluded from all insurance formularies, including Anthem. Compounded semaglutide must be paid out-of-pocket. FormBlends offers compounded semaglutide at $297/month with no insurance accepted.

What is prior authorization and how long does it take with Anthem? Prior authorization is a requirement that your provider submit clinical documentation to Anthem before the medication is covered. Anthem reviews within 72 hours (standard) or 24 hours (expedited). About 41% of requests are denied on first submission, usually due to incomplete documentation. Resubmission with complete records has a 62% approval rate.

Can I get Anthem to cover Ozempic for weight loss if I don't have diabetes? No. Ozempic is FDA-approved only for Type 2 diabetes. Anthem will not cover off-label use for weight loss. If you do not have diabetes, the appropriate medication is Wegovy (the same molecule, semaglutide, approved for obesity), which requires the obesity treatment rider and prior authorization.

Does Anthem cover Saxenda? Yes, if your plan includes an obesity treatment rider and you meet prior authorization criteria. Saxenda (liraglutide) is an older GLP-1 medication with lower efficacy than Wegovy or Zepbound. Some Anthem plans place Saxenda on a lower formulary tier (cheaper copay) and require step therapy (try Saxenda before Wegovy).

What happens if I lose weight and my BMI drops below 27 on Anthem coverage? Most Anthem plans terminate coverage when BMI drops below the eligibility threshold (typically BMI <27). This creates a "success penalty" where effective treatment is discontinued, often leading to weight regain. A 2024 study found 64% of patients regain weight within 12 months of forced discontinuation.

Does Anthem cover weight loss medication for PCOS? Only if you meet the standard criteria (BMI ≥30 or ≥27 with comorbidity). PCOS alone does not qualify. However, if you have PCOS and meet BMI criteria, PCOS can count as a comorbidity (insulin resistance, metabolic syndrome). Your provider must document this in the prior authorization request.

Can I use a manufacturer coupon for Wegovy or Zepbound with Anthem insurance? It depends. Manufacturer coupons (Novo Nordisk savings card for Wegovy, Lilly savings card for Zepbound) reduce out-of-pocket costs but are not accepted by all plans. Anthem commercial plans usually allow coupons. Anthem Medicare Advantage plans prohibit coupons by federal law. Check the coupon terms and your plan's coupon policy.

How do I find out if my Anthem plan covers weight loss medications? Call the member services number on your insurance card and ask: "Does my plan include coverage for weight loss medications prescribed for obesity?" Request a written summary of benefits or the specific policy section. Do not rely on the Anthem website formulary search alone, as it does not show whether your specific plan includes the obesity rider.

What is step therapy and does Anthem require it for GLP-1 weight loss medications? Step therapy (fail first) requires you to try a cheaper medication (orlistat or phentermine) before Anthem will cover a GLP-1 medication. About 47% of Anthem commercial plans include step therapy for weight loss medications. Check your plan document or ask member services.

Does Anthem cover weight loss surgery instead of medication? Most Anthem plans cover bariatric surgery (gastric bypass, sleeve gastrectomy) with prior authorization. Criteria are typically BMI ≥40, or BMI ≥35 with comorbidities, plus documented failure of non-surgical weight loss attempts. Surgery coverage is more common than medication coverage because the one-time cost is often lower than years of medication.

Can I appeal an Anthem denial for weight loss medication? Yes. The appeal process has two steps: internal appeal (Anthem reviews within 30 days) and external review (independent third party, decision is binding). Appeal success rates are 28% for internal and 38% for external. Appeals are worth pursuing if the denial was due to incomplete documentation or if you are just below the BMI threshold with strong comorbidities.

Does Anthem cover weight loss medication for teenagers? Wegovy is FDA-approved for adolescents age 12+ with BMI ≥95th percentile for age and sex. Anthem plans that include obesity coverage extend it to adolescents meeting FDA criteria. Prior authorization is required and criteria are the same as adults: documented lifestyle intervention, no contraindications.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Conti RM et al. Coverage Termination After Weight Loss Success in Commercial Insurance. Health Affairs. 2024.
4. Arterburn DE et al. Real-World Weight Loss Outcomes with GLP-1 Receptor Agonists. Obesity. 2025.
5. Khera R et al. Off-Label GLP-1 Prescribing Patterns in Medicare. JAMA Internal Medicine. 2024.
6. Hoadley J et al. Appeal Rates and Outcomes for Prior Authorization Denials. Health Affairs. 2023.
7. Purchaser Business Group on Health. Large Employer Health Benefits Survey. 2025.
8. Kaiser Family Foundation. Employer Health Benefits Annual Survey. 2025.
9. Academy of Managed Care Pharmacy. Step Therapy Utilization Trends. 2025.
10. American Association of Clinical Endocrinology. Position Statement on Step Therapy for Obesity Medications. 2024.
11. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination Regulations, 42 CFR 423.100. 2024.
12. National Association of Insurance Commissioners. External Review Data Report. 2024.
13. Davies MJ et al. Gastric Emptying Effects of Tirzepatide in Obesity. Diabetes Care. 2023.
14. American College of Gastroenterology. GERD Guidelines. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Anthem is a registered trademark of Anthem Insurance Companies, Inc. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Xenical is a registered trademark of Roche. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.